Business Combination, Contingent Consideration, Liability
Vertex Pharmaceuticals Business Combination, Contingent Consideration, Liability increased by 0.3% to $79.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.1%, from $79.10M to $79.20M. Over 5 years (FY 2020 to FY 2025), Business Combination, Contingent Consideration, Liability shows a downward trend with a -16.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase suggests the acquired business is meeting or exceeding performance targets, which will require higher future cash payouts.
Detailed definition
This represents the fair value of a liability recognized when the company is obligated to pay additional consideration t...
Peer comparison
This is a standard liability for companies pursuing aggressive M&A strategies with performance-based earn-out structures.
other_business_combination_contingent_consideration_liabilityHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $187.30M | $188.50M | $186.50M | $179.00M | $129.80M | $127.20M | $129.00M | $127.10M | $126.50M | $127.70M | $77.40M | $77.30M | $77.80M | $78.10M | $76.90M | $79.10M | $80.00M | $78.10M | $79.00M | $79.20M |
| QoQ Change | — | +0.6% | -1.1% | -4.0% | -27.5% | -2.0% | +1.4% | -1.5% | -0.5% | +0.9% | -39.4% | -0.1% | +0.6% | +0.4% | -1.5% | +2.9% | +1.1% | -2.4% | +1.2% | +0.3% |
| YoY Change | — | — | — | — | -30.7% | -32.5% | -30.8% | -29.0% | -2.5% | +0.4% | -40.0% | -39.2% | -38.5% | -38.8% | -0.6% | +2.3% | +2.8% | +0.0% | +2.7% | +0.1% |
Business Combination, Contingent Consideration, Liability at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's business combination, contingent consideration, liability?
- Vertex Pharmaceuticals (VRTX) reported business combination, contingent consideration, liability of $79.20M in Q1 2026.
- How has Vertex Pharmaceuticals's business combination, contingent consideration, liability changed year-over-year?
- Vertex Pharmaceuticals's business combination, contingent consideration, liability increased by 0.1% year-over-year, from $79.10M to $79.20M.
- What is the long-term trend for Vertex Pharmaceuticals's business combination, contingent consideration, liability?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's business combination, contingent consideration, liability has grown at a -16.1% compound annual growth rate (CAGR), from $189.60M to $79.00M.
- What does business combination, contingent consideration, liability mean?
- The estimated amount the company expects to pay in the future based on the performance of an acquired business.